Characterization of single amino acid substitutions in the $\beta 2$ integrin subunit of patients with leukocyte adhesion deficiency (LAD)-1

Guan, Siyu; Tan, Suet-Mien; Li, Yan; Torres, Jaume; Uzel, Gulbu; Xiang, Liming; Law, S.K. Alex

2015

Guan, S., Tan, S.-M., Li, Y., Torres, J., Uzel, G., Xiang, L., et al. (2015). Characterization of single amino acid substitutions in the $\beta 2$ integrin subunit of patients with leukocyte adhesion deficiency (LAD)-1. *Blood cells, molecules, and diseases*, 54(2), 177-182.

<https://hdl.handle.net/10356/106915>

<https://doi.org/10.1016/j.bcmd.2014.11.005>

© 2014 Elsevier Inc. This is the author created version of a work that has been peer reviewed and accepted for publication by *Blood Cells, Molecules, and Diseases*, Elsevier Inc. It incorporates referee's comments but changes resulting from the publishing process, such as copyediting, structural formatting, may not be reflected in this document. The published version is available at: [<http://dx.doi.org/10.1016/j.bcmd.2014.11.005>].

Downloaded on 26 Apr 2023 17:33:20 SGT

Characterization of single amino acid substitutions in the $\beta 2$ integrin subunit of patients with leukocyte adhesion deficiency (LAD)-1

Siyu Guan^a, Suet-Mien Tan^a, Yan Li^a, Jaume Torres^a, Gulbu Uzel^b, Liming Xiang^c, and S. K. Alex Law^{a,*}

^a School of Biological Sciences, Nanyang Technological University, Singapore

^b Laboratory of Infectious Disease, National Institute of Allergy and Infectious Diseases, National Institute of Health, Bethesda, Maryland, USA

^c School of Physical and Mathematical Sciences, Nanyang Technological University, Singapore

Abstract

Leukocyte Adhesion Deficiency 1 (LAD-1) is caused by defects in the $\beta 2$ integrin subunit. We studied 18 missense mutations, 14 of which fail to support the surface expression of the $\beta 2$ integrins. Integrins with the $\beta 2$ -G150D mutation fail to bind ligands, possibly due to the failure of the $\alpha 1$ segment of the $\beta 1$ domain to assume an α -helical structure. Integrins with the $\beta 2$ -G716A mutation are not maintained in their resting states, and the patient has the severe phenotype of LAD-1. The $\beta 2$ -S453N and $\beta 2$ -P648L mutants support the expression of integrins and adhesion functions. They should be re-classified as polymorphic variants.

* Corresponding author at: School of Biological Sciences, Nanyang Technological University, 60 Nanyang Drive, Singapore 637551. Fax: +65 6515 1632

Email address: alaw@ntu.edu.sg

Keywords

LAD-1
Missense Mutation
 β 2 (CD18) Integrin
Expression
Cell Adhesion

Abbreviations

LAD-1, Leukocyte adhesion deficiency-1; LFA-1, Leukocyte function associated antigen-1 (α L β 2); Mac-1, Macrophage antigen-1 (α M β 2); ICAM, Intercellular adhesion molecule; BSA, Bovine serum albumin; WT, Wild-type, NMR, Nuclear magnetic resonance

Highlights

- Complete the functional characterization on LAD-1 missense mutations.
- Systematic analysis of integrin adhesion using two-sample Hotelling's T-square test.
- G150D highlights the importance of α 1 helix conformation in the β I domain with respect to ligand binding.
- Summarize *in vitro* characteristics related to all LAD-1 missense mutations identified to date in Table 1.

1. Introduction

Leukocyte Adhesion Deficiency-1 (LAD-1) is caused by defects in the *ITGB2* gene which codes for the $\beta 2$ integrin subunit, resulting in the depressed expression of the $\beta 2$ leukocyte integrin family members, the $\alpha L\beta 2$, $\alpha M\beta 2$, $\alpha X\beta 2$ and $\alpha D\beta 2$ integrins, or the expression of their non-functional forms. The $\alpha L\beta 2$ integrin is also referred to as the leukocyte function associated antigen-1 (LFA-1), and CD11a/CD18 in the leukocyte antigen nomenclature; and similarly, $\alpha M\beta 2$ the macrophage antigen-1 (Mac-1) and CD11b/CD18; $\alpha X\beta 2$ the p150,95 antigen and CD11c/CD18; and $\alpha D\beta 2$ the CD11d/CD18 antigen. The leukocytes of patients with LAD-1 are defective in various adhesion functions, including the migration from blood to tissue sites of infection and inflammation. Consequently, the patients suffer from recurrent bacterial and fungal infections. Depending on the severity of the disease, may die at an early age [1-3].

In 2012, van de Vijver et al updated the mutant alleles leading to LAD-1 [4]. They include 23 deletions, 2 insertions, 4 deletion/insertions, 10 nonsense mutations, 12 splice site mutations, and 35 missense mutations . Whereas the mutations in the first five categories invariably lead to the non-expression of the $\beta 2$ integrins, the missense mutations could result in many molecular phenotypes. Most of them do not support integrin heterodimer expression, others support normal expression levels of integrin heterodimers which are non adhesive, yet others support subnormal level of integrin heterodimers with residual adhesion functions, and a few mutations support the expression of integrins in their non-resting states. Seventeen of the 35 missense mutations were reported previously for their capacity to support of integrin heterodimer expression, and their adhesion functions. More detailed information can

be found in the summary Table 1 [2, 5-29]. In this article, we complete this line of investigation on the remaining 18 missense mutations.

The location of the 18 missense mutations is shown in the schematic map in Figure 1. The alignment of these variants to the local sequences of the 8 human β integrin subunits is shown in Figure 2. The numbering of the amino acids of the polypeptide is such that “1” is for the initiation methionine.

2. Materials and methods

2.1. Antibodies and reagents

Hybridoma of mAbs were obtained from different sources: MHM24 (anti- α L blocking mAb) and MHM23 (β 2 heterodimer specific mAb) [30] and H52 (β 2-specific mAb) [31] were provided by Professor AJ McMichael (John Radcliff Hospital, Oxford, UK). KIM185 (anti- β 2 activating mAb) [32] was obtained from Dr. MK Robinson (UCB, CellTech, UK). LPM19C (anti- α M blocking mAb) [33] and 1B4 (function blocking mAB, β 2 heterodimer specific) [34] were purchased from ATCC. All mAb were purified from hybridoma supernatant using Hi-Trap protein G or A columns (Amersham Pharmacia Biotech). Preparation of recombinant human ICAM-1-Fc and ICAM-3-Fc was described previously [35]. Bovine serum albumin (fraction V, BSA) was purchased from Sigma-Aldrich.

2.2 cDNA expression plasmids

The pcDNA3 expression plasmids containing α L, α M, α X and β 2 cDNA were described previously [22]. LAD-1 mutations were generated using site-directed

mutagenesis kit (Stratagene) following the manufacturer's protocols. All constructs were verified by sequencing (1st Base, Singapore).

2.3. *Cell culture and transfection*

Human embryonic kidney 293T (HEK293T) cells were purchased from ATCC, cells were cultured in DMEM (Hyclone) supplemented with 10% (v/v) heat-inactivated FBS (Hyclone), 100 IU/ml penicillin and 100 µg/ml streptomycin (Hyclone) at 37°C in 5% CO₂ humidified incubator. HEK293T cells were transfected with expression plasmids using Polyethylenimine (PEI) according to a previously described method [36].

2.4. *Flow cytometry*

Surface expression of the β2 integrins was determined by flow cytometry on a FACS caliber (BD Bioscience) [10] with the heterodimer specific mAb MHM23 [5,6]. detection was described previously [35]. Data were analyzed using Flowjo (Tree Star).

2.5. *Cell adhesion assay*

For ICAM-1 and ICAM-3 adhesion, 100 µl of 5 µg/ml goat anti-human IgG (Fc specific) (Sigma-Aldrich) in bicarbonate buffer (50 mM, pH 9.2) was introduced into each well in 96-well microtiter plates (Polysorb, Nunc Immno-Plate) and left overnight at 4°C. Non-specific sites were blocked with 130 µl of 0.5% (w/v) BSA in PBS for each well. 50 µl of ICAM-1-Fc or ICAM-3-Fc in PBS with 0.1% BSA (w/v) at 1 µg/ml was added into each well and left at RT for 2 hours. For BSA adhesion assay, 100 µl of 100 µg/ml BSA in bicarbonate buffer was coated on each well and

the plate was left overnight at 4°C. Non-specific sites were blocked with 130 µl of 0.2% (w/v) polyvinylpyrrolidone (PVP) in PBS for each well. In all cases the wells were washed twice with wash buffer (RPMI1640 with 10 mM HEPES and 5% v/v FBS) before adding cells. Transfected cells were harvested, washed and incubated with 1 µg/ml BCECF (Invitrogen) in wash buffer at 37°C for 20 min. Labeled cells were transferred to each wells with or without activation reagents (Mg^{2+} /EGTA: 5 mM $MgCl_2$ and 1.5 mM EGTA; Mn^{2+} : 0.5 mM $MnCl_2$; mAb KIM185: 10 µg/ml) and incubated at 37°C for 30 min. To establish specificity, appropriate antibodies were added to block adhesion. Unbound cells were removed by washing twice with wash buffer. Fluorescence signal, which correlates with the number of cells adhering to the ligand-coated well, was measured using a FL600 fluorescence plate reader (Bio-Tek instruments, Winooski, VT).

2.6. *Peptide synthesis*

Peptides were synthesized using 9-fluorenyl-methyloxycarbonyl (Fmoc) solid-phase chemistry (Liberty Microwave Peptide Synthesizer, CEM North Carolina, USA) and Tentagel amide resin (Intavis AG, Germany). The peptides were cleaved from the resin with trifluoroacetic acid (TFA). The lyophilized peptides were dissolved in a water-acetonitrile mixed solvent, injected into a C18 HPLC column, and eluted with a linear gradient of water/acetonitrile, from 0% to 100% acetonitrile. Peptide purity was confirmed by electrospray ionization (ESI) mass spectrometry. The purified peptides were lyophilized overnight after the addition of 10 mM HCl, to remove possible TFA adducts.

2.7. *NMR data collection and structure calculation*

NMR experiments were performed at 298K using an Avance-II 700 NMR spectrometer with cryogenic probe. Sodium 2,2-dimethyl-2-silapentane-5-sulfonate (DSS) was used as the internal reference for ^1H nuclei. NMR data were processed using TopSpin 3.1 (www.bruker-biospin.com) and analyzed using CARA (www.nmr.ch). Sequence-specific resonance assignments of the peptides were achieved from two-dimensional total correlation spectroscopy (TOCSY) and nuclear Overhauser effect spectroscopy (NOESY) spectra acquired in PBS buffer containing 0.5 mM glucose at pH 7.4. The peptide concentrations were 1 mM, and mixing times were 80 and 200 ms for TOCSY and NOESY, respectively. For structure calculation, NOE distance restraints were obtained from NOESY spectra. The short-range and medium range NOE connectivities were used to establish the sequence-specific ^1H NMR assignment and to identify elements of regular secondary structure. All the restraints used in the calculations are listed in Supplementary Tables 1 ($\beta 2$ peptides) and 2 ($\beta 3$ peptides). Structure calculations were performed using CYANA 3.0 [37, 38] and visualized using PyMOL (Delano Scientific). A total of 10 structures were calculated and the structure statistics are summarized in the Supplementary Tables.

2.8. Statistics

Adhesion profile of each mutant was compared to that of its corresponding wild-type. Each profile consisted of at least three conditions, which are highly correlated with one another. In order to study all conditions simultaneously, a multivariate two-sample comparison, Hotelling's T^2 test was conducted. This test is a multivariate analog of the ordinary t-test in the univariate statistics and extends the idea of the t-test to analyze statistical significance holistically for the combined set of conditions. Multivariate statistical methods have become increasingly popular and desirable in

the analysis of data from complex biological assays [39, 40]. It has the unique advantages of taking variant factors simultaneously and is capable of describing differences between graph patterns, which are the major concerns in this characteristic work aiming to understand the function profiling under comprehensive conditions for each of the mutants.

The binding values of conditions in Fig. 4A, 4C, 4D (namely sham, Mg^{2+} /EGTA or Mn^{2+} , KIM185,) were treated as a 3-dimensional vector. In Fig. 4B, one additional condition (Mg^{2+} /EGTA plus KIM185) returned a vector of 4 dimensions. A comparison was made between a group of vectors (triplet or quadruplet) of conditions for each mutant and that for the corresponding wild-type. Note that there was no evidence that assumption of homogeneous variance-covariance matrices was violated for all tests. Data were analyzed using SAS (statistical analysis system) software. It should be noted that only the data obtained without the blocking antibodies, which were used to establish binding specificity, were analyzed.

3. Results and Discussion

Each of the 18 mutations was introduced into a wild-type $\beta 2$ integrin cDNA expression plasmid. These plasmids were co-transfected into HEK293T cells with the expression plasmids of the αL , αM , or αX subunit. Surface expression of the $\alpha L\beta 2$, $\alpha M\beta 2$ and $\alpha X\beta 2$ integrins was determined by flow cytometry using the heterodimer specific mAb MHM23. The results on $\alpha L\beta 2$ expression are shown in Figure 3. Four of the missense mutations G150D, S453N, P648L, and G716A supported the heterodimer expression of $\alpha L\beta 2$. The $\alpha M\beta 2$ and $\alpha X\beta 2$ expression

profiles with the 18 $\beta 2$ mutants are similar to those of $\alpha L\beta 2$. They are shown in the Supplementary Figure A1. The 14 mutations which did not support heterodimer surface expression were capable in forming CD18 protein as tested by anti- $\beta 2$ conformational mAb H52 and KIM185 after cell permeabilization (data not shown).

The four mutants that support heterodimer expression were subjected to adhesion analyses. Normally, the wild-type $\alpha L\beta 2$ would require either the presence of Mg^{2+} /EGTA or the activating mAb KIM185 for adhesion to ICAM-1, but would require the presence of both reagents to adhere to ICAM-3 [26, 41].

Tansfectants expressing $\alpha L\beta 2$ of the S453N, and P648L mutations showed wild-type adhesion properties to ICAM-1 and ICAM-3. Cells expressing $\alpha L\beta 2$ with G150D showed no adhesion to either ligand on all conditions (Figure 4A, B). Cells expressing $\alpha L\beta 2$ with G716A showed similar adhesive property to ICAM-1 as the wild-type (no significant difference at the level of 0.05). However, the difference in adhesion appears more clearly in the binding to ICAM-3, in which $\alpha L\beta 2$ - G716A required only Mg^{2+} /EGTA or KIM185 to adhere to ICAM-3 (Figure 4B), suggesting that the overall adhesion property of $\alpha L\beta 2$ with G716A is different from (more adhesive than) that of the wild-type.

Similarly, cells expressing $\alpha M\beta 2$ and $\alpha X\beta 2$ with the S453N, and P648L mutations were wild-type like in their adhesion to denatured BSA; whereas those with G150D showed no adhesion to the ligand. The distinction between the adhesion profiles of $\alpha M\beta 2$ and $\alpha X\beta 2$ with G716A, in comparison to their respective wild-types, is significant (Figure 4C, D).

3.1. *S453N and P648L*

The two proposed mutations, S453N and P648L, were reported in two individuals but their LAD-1 status was not very definitive. The two mutations were identified by sequencing genomic DNA exons and splicing sites of introns, no other mutation could be identified. With the results presented here, it is likely that they represent rare polymorphisms found in the *ITGB2* gene. In fact, recent statistics shows that S453N has a frequency of ~0.2% in European cohorts (RS#13865490).

3.2. *G150D*

The G150D mutation was identified in a patient born to unrelated parents. He has decreased surface expression of the $\beta 2$ integrins on his neutrophils. The patient is a compound heterozygote, the other mutation is P178L. It was previously reported that the P178L mutation in the $\beta 2$ integrin subunit does not support integrin heterodimer expression of the $\alpha L\beta 2$, $\alpha M\beta 2$ and $\alpha X\beta 2$ integrins [19]. Thus the expression of the integrins on his leukocytes is due to the G150D allele. Our experimental results are in agreement with this finding. Two other mutations, S138P [12] and D231H [20], were reported previously to be capable to support heterodimer expression but not adhesion. S138 is the coordinating residue of the divalent cation binding motif MIDAS in the βI domain [42], and D231 that of the synergistic metal ion binding site SyMBS [43], and may therefore account for the lack of adhesion functions of these mutants. G150 is also located in the βI domain. In the closed and bent structure of the $\alpha X\beta 2$ ectodomain, the $\alpha 1$ and $\alpha 1'$ helices of the βI domain are discontinuous, and G150 is located at the N-terminal of the $\alpha 1'$ helix [43]. Upon activation, the $\alpha 1$

helix of $\alpha\text{X}\beta 2$ become extended and the G150 residue is inside the extended helix [44] (see Figure 5A and B).

We synthesized the $\beta 2$ peptides spanning the $\alpha 1$ and $\alpha 1'$ helices with the wild-type glycine or the mutant aspartic acid. NMR analysis showed that whereas the wild-type peptide with the glycine is a continuous helix, the one with the aspartic acid is not (Figure 5C and D). We may therefore tentatively argue that the aspartic acid would prevent the $\beta 2$ integrins to assume its active state, resulting in integrins with no adhesion functions. However, such conclusion can only be established if the entire ectodomain structures of the wild-type and mutant integrin can be compared.

3.3. G716A

G716A is the first LAD-1 mutation found in the $\beta 2$ transmembrane region. In a study on the effect of various residues in the transmembrane region by phenylalanine scanning, it was found that the mutation of this glycine to a phenylalanine would confer an intermediate activation state to the $\alpha\text{L}\beta 2$ integrin. By model building, G716 of $\beta 2$ faces the L1104 of αL in the $\alpha\text{L}\beta 2$ heterodimer, and this orientation is also consistent with later NMR titration experiments of αL TM with $\beta 2$ TM in micelles [45].

The replacement of G716 with a phenylalanine would have two bulky residues facing each other, resulting in the leg separation of the integrin, and its promotion to the next activation state [46]. In this study, we showed that by changing the glycine to an alanine is sufficient to cause activation. It seems that the proper packaging of

the transmembrane region at this site is necessary to maintain LFA-1 in the resting state.

Perhaps the more curious observation is why such mutations would confer LAD-1 to the patients, in particular with the very low expression of the $\beta 2$ integrins on the patients' leukocytes. There were two cases reported previously. Similar to G716A, the C590R and R593C mutations were able to support the expression $\alpha L\beta 2$ integrin, in an expression system using COS-7 cells, at the intermediate activation state [22]. However, unlike G716A, these two mutations do not support the expression of the $\alpha M\beta 2$ and $\alpha X\beta 2$ integrins in this artificial expression system. Recently, it was reported in a patient with the classic leukocyte adhesion deficiency symptoms including delayed umbilical cord separation and recurrent bacterial infection, but does not have the mutations in the genes associated with LAD-1 and LAD-II. His normal platelet function also excludes him for having LAD-III. Interestingly, his leukocytes were found to be hyperadhesive and slow in migration [47]. This report is therefore in line with our observation that LAD-1 patients expressing hyperadhesive integrins could display the symptoms of leukocyte adhesion deficiency.

4. Conclusion

We have characterized 16 novel missense mutations in the $\beta 2$ integrin subunit. We have also shown that the mutation status of the S453N and P648L has to be re-evaluated and they are likely to be rare polymorphisms of the *ITGB2* gene. The mutants with the G150D and G716A have provided novel insights in the regulation of the structure and functions of the $\beta 2$ integrins. A table that listed the *in vitro*

characteristics of all 35 LAD-1 missense mutations (including 16 in this work) was summarized (Table 1).

Acknowledgements

This work was supported by Tier 1 grant from Nanyang Technological University Academic Research Fund (AcRF) RG 93/07.

Appendix A. Supplementary data

References

1. Anderson DC, Springer TA. Leukocyte Adhesion Deficiency - an Inherited Defect in the Mac-1, Lfa-1, and P150,95 Glycoproteins. *Annu Rev Med* 1987; 38:175-94.
2. Arnaout MA, Dana N, Gupta SK, Tenen DG, Fathallah DM. Point Mutations Impairing Cell-Surface Expression of the Common Beta-Subunit (Cd-18) in a Patient with Leukocyte Adhesion Molecule (Leu-Cam) Deficiency. *J Clin Invest* 1990; 85(3):977-81.
3. Roos D, Law SKA. Hematologically important mutations: Leukocyte adhesion deficiency. *Blood Cell Mol Dis* 2001; 27(6):1000-4.
4. van de Vijver E, Maddalena A, Sanal O, *et al.* Hematologically important mutations: Leukocyte adhesion deficiency (first update). *Blood Cell Mol Dis* 2012; 48(1):53-61.
5. Sligh JE Jr HM, Zhu CM, Anderson DC, Beaudet AL. An initiation codon mutation in CD18 in association with the moderate phenotype of leukocyte adhesion deficiency. *J Biol Chem* 1992; 267(January 15):714-8.
6. Tng E, Tan SM, Ranganathan S, Cheng M, Law SKA. The integrin alpha(L)beta(2) hybrid domain serves as a link for the propagation of activation signal from its stalk regions to the I-like domain. *J Biol Chem* 2004; 279(52):54334-9.
7. Hinze CH, Lucky AW, Bove KE, Marsh RA, Bleesing JH, Passo MH. Leukocyte Adhesion Deficiency Type 1 Presenting with Recurrent Pyoderma Gangrenosum and Flaccid Scarring. *Pediatr Dermatol* 2010; 27(5):500-3.
8. Matsuura S, Kishi F, Tsukahara M, Nunoi H, Matsuda I, Kobayashi K, Kajii T. Leukocyte Adhesion Deficiency - Identification of Novel Mutations in 2 Japanese Patients with a Severe Form. *Biochem Bioph Res Co* 1992; 184(3):1460-7.

9. Parvaneh N, Mamishi S, Rezaei A, *et al.* Characterization of 11 New Cases of Leukocyte Adhesion Deficiency Type 1 with Seven Novel Mutations in the ITGB2 Gene. *J Clin Immunol* 2010; 30(5):756-60.
10. Uzel G, Tng E, Rosenzweig SD, *et al.* Reversion mutations in patients with leukocyte adhesion deficiency type-1 (LAD-1). *Blood* 2008; 111(1):209-18.
11. Lorusso F, Kong D, Abdul Jalil AK, Sylvestre C, Tan SL, Ao S. Preimplantation genetic diagnosis of leukocyte adhesion deficiency type I. *Fertil Steril* 2006; 85(2).
12. Hogg N, Stewart MP, Scarth SL, Newton R, Shaw JM, Law SKA, Klein N. A novel leukocyte adhesion deficiency caused by expressed but nonfunctional beta 2 integrins Mac-1 and LFA-1. *J Clin Invest* 1999; 103(1):97-106.
13. Wardlaw AJ, Hibbs ML, Stacker SA, Springer TA. Distinct Mutations in 2 Patients with Leukocyte Adhesion Deficiency and Their Functional Correlates. *J Exp Med* 1990; 172(1):335-45.
14. Wright AH, Douglass WA, Taylor GM, Lau YL, Higgins D, Davies KA, Law SKA. Molecular Characterization of Leukocyte Adhesion Deficiency in 6 Patients. *Eur J Immunol* 1995; 25(3):717-22.
15. Uzel G, Kuhns D, Hussey A, Spalding C, Stoddard J, Hsu A, Holland S. The new face of leukocyte adhesion deficiency type 1 (LAD-1). XIVth Meeting of the European Society for Immunodeficiencies 2010:132 (Abstr. P256).
16. Corbi AL, Vara A, Ursa A, Rodriguez MCG, Fontan G, Sanchezmadrid F. Molecular-Basis for a Severe Case of Leukocyte Adhesion Deficiency. *Eur J Immunol* 1992; 22(7):1877-81.
17. Back AL, Kwok WW, Hickstein DD. Identification of 2 Molecular Defects in a Child with Leukocyte Adherence Deficiency. *J Biol Chem* 1992; 267(8):5482-7.
18. Ohashi Y, Yambe T, Tsuchiya S, Kikuchi H, Konno T. Familial Genetic-Defect in a Case of Leukocyte Adhesion Deficiency. *Hum Mutat* 1993; 2(6):458-67.
19. Malawista SE, Chevance AD, Brown EJ, Boxer LA, Law SKA. Chemotaxis of non-compressed blood polymorphonuclear leukocytes from an adolescent with severe leukocyte adhesion deficiency. *Am J Hematol* 2003; 73(2):115-20.
20. Mathew EC, Shaw JM, Bonilla FA, Law SKA, Wright DA. A novel point mutation in CD18 causing the expression of dysfunctional CD11/CD18 leucocyte integrins in a patient with leucocyte adhesion deficiency (LAD). *Clin Exp Immunol* 2000; 121(1):133-8.
21. Roos D, Meischl C, de Boer M, *et al.* Genetic analysis of patients with leukocyte adhesion deficiency: Genomic sequencing reveals otherwise undetectable mutations. *Exp Hematol* 2002; 30(3):252-61.
22. Shaw JM, Al-Shamkhani A, Boxer LA, *et al.* Characterization of four CD18 mutants in leucocyte adhesion deficient (LAD) patients with differential capacities to support expression and function of the CD11/CD18 integrins LFA-1, Mac-1 and p150,95. *Clin Exp Immunol* 2001; 126(2):311-8.
23. Li L, Jin YY, Cao RM, Chen TX. A novel point mutation in CD18 causing leukocyte adhesion deficiency in a Chinese patient. *Chinese Med J-Peking* 2010; 123(10):1278-82.
24. Nelson C, Rabb H, Arnaout MA. Genetic Cause of Leukocyte Adhesion Molecule Deficiency - Abnormal Splicing and a Missense Mutation in a Conserved Region of Cd18 Impair Cell-Surface Expression of Beta-2 Integrins. *J Biol Chem* 1992; 267(5):3351-7.

25. Crowley CA, Curnutte JT, Rosin RE, *et al.* An Inherited Abnormality of Neutrophil Adhesion - Its Genetic Transmission and Its Association with a Missing Protein. *New Engl J Med* 1980; 302(21):1163-8.
26. Cheng M, Foo SY, Shi ML, Tang RH, Kong LS, Law SKA, Tan SM. Mutation of a conserved asparagine in the I-like domain promotes constitutively active integrins $\alpha(L)ss(2)$ and $\alpha(IIb)ss(3)$. *J Biol Chem* 2007; 282(25):18225-32.
27. Fathallah DM, Jamal, T., Barbouche, M.R., Bejaoui, M., Hariz, M.B., Dellagi, K. Two novel frame shift, recurrent and de novo mutations in the ITGB2 (CD18) gene causing leukocyte adhesion deficiency in a highly inbred North African population. *J Biomed Biotechnol* 2001; 1(3):114-21.
28. Eyerich K, Cifaldi L, Notarangelo LD, *et al.* Chronic eczema in a patient with Leukocyte Adhesion Deficiency (LAD) type I. *Eur J Dermatol* 2009; 19(1):78-9.
29. Fiorini M, Vermi W, Facchetti F, *et al.* Defective migration of monocyte-derived dendritic cells in LAD-1 immunodeficiency. *J Leukocyte Biol* 2002; 72(4):650-6.
30. Hildreth JEK, Gotch FM, Hildreth PDK, Mcmichael AJ. A Human Lymphocyte-Associated Antigen Involved in Cell-Mediated Lympholysis. *Eur J Immunol* 1983; 13(3):202-8.
31. Hildreth JEK, August JT. The Human-Lymphocyte Function-Associated (Hlfa) Antigen and a Related Macrophage Differentiation Antigen (Hmac-1) - Functional-Effects of Subunit-Specific Monoclonal-Antibodies. *J Immunol* 1985; 134(5):3272-80.
32. Robinson MK, Andrew D, Rosen H, Brown D, Ortlepp S, Stephens P, Butcher EC. Antibody against the Leu-Cam Beta-Chain (Cd18) Promotes Both Lfa-1-Dependent and Cr3-Dependent Adhesion Events. *J Immunol* 1992; 148(4):1080-5.
33. Uciechowski P, Schmidt RE. NK and non-lineage antigens cluster report: CD11. . In *Leukocyte Typing IV: White Cell Differentiation Antigens* 1989; W. Knapp, editor . Oxford University Press, Oxford .543-51.
34. Wright SD, Vanvoorhis WC, Silverstein SC. Identification of the C3b'-Receptor on Human-Leukocytes Using a Monoclonal-Antibody. *Fed Proc* 1983; 42(4):1079-.
35. Tan SM, Hyland RH, Al-Shamkhani A, Douglass WA, Shaw JM, Law SKA. Effect of integrin beta(2) subunit truncations on LFA-1 (CD11a/CD18) and Mac-1 (CD11b/CD18) assembly, surface expression, and function. *J Immunol* 2000; 165(5):2574-81.
36. Durocher Y, Perret S, Kamen A. High-level and high-throughput recombinant protein production by transient transfection of suspension-growing human 293-EBNA1 cells. *Nucleic Acids Res* 2002; 30(2).
37. Guntert P, Mumenthaler C, Wuthrich K. Torsion angle dynamics for NMR structure calculation with the new program DYANA. *J Mol Biol* 1997; 273(1):283-98.
38. Herrmann T, Guntert P, Wuthrich K. Protein NMR structure determination with automated NOE assignment using the new software CANDID and the torsion angle dynamics algorithm DYANA. *Journal of Molecular Biology* 2002; 319(1):209-27.
39. Lu Y, Liu PY, Xiao P, Deng HW. Hotelling's T2 multivariate profiling for detecting differential expression in microarrays. *Bioinformatics* 2005; 21(14):3105-13.

40. Saeys Y, Inza I, Larranaga P. A review of feature selection techniques in bioinformatics. *Bioinformatics* 2007; 23(19):2507-17.
41. Tang XY, Li YF, Tan SM. Intercellular adhesion molecule-3 binding of integrin α (L) β (2) requires both extension and opening of the integrin headpiece. *J Immunol* 2008; 180(7):4793-804.
42. Bajt ML, Goodman T, McGuire SL. β (2) (Cd18) Mutations Abolish Ligand Recognition by I-Domain Integrins Lfa-1 (α (L) β (2), Cd11a/Cd18) and Mac-1 (α (M) β (2), Cd11b/Cd18). *J Biol Chem* 1995; 270(1):94-8.
43. Xie C, Zhu JH, Chen X, Mi LZ, Nishida N, Springer TA. Structure of an integrin with an α I domain, complement receptor type 4. *Embo J* 2010; 29(3):666-79.
44. Sen M, Yuki K, Springer TA. An internal ligand-bound, metastable state of a leukocyte integrin, α X β 2. *The Journal of cell biology* 2013; 203(4):629-42.
45. Surya W, Li Y, Millet O, Diercks T, Torres J. Transmembrane and Juxtamembrane Structure of α L Integrin in Bicelles. *PLoS One* 2013; 8(9):e74281.
46. Vararattanavech A, Chng CP, Parthasarathy K, Tang XY, Torres J, Tan SM. A Transmembrane Polar Interaction Is Involved in the Functional Regulation of Integrin α L β 2. *J Mol Biol* 2010; 398(4):569-83.
47. Simpson BN, Hogg N, Svensson LM, McDowall A, Daley W, Yarbrough K, Abdul-Rahman OA. A new leukocyte hyperadhesion syndrome of delayed cord separation, skin infection, and nephrosis. *Pediatrics* 2014; 133(1):e257-62.

Figure Legends

- Fig. 1. The location of the LAD-1 mutations to the various domains of the β 2 integrin subunit.
- Fig. 2. Local sequence alignment of the 8 human integrin subunits flanking the mutated residues. The mutated residues are shown in bold at the top of the aligned sequences.
- Fig. 3. Flow cytometry analysis of the surface expression of α L β 2 (LFA-1) transfectants with the various mutations. The mAb used was MHM23 which is specific for the β 2 integrin heterodimers [30]. The background histograms were obtained with LPM19c (α M-specific).
- Fig. 4. Adhesion of α L β 2 transfectants to ICAM-1 (A), and ICAM-3 (B). The forward bars were adhesion in the presence of the function-blocking mAb MHM24. Adhesion of α M β 2 (C) and α X β 2 (D) to denatured BSA. The forward bars were adhesion in the presence of the function-blocking mAb LPM19c (C) and 1B4 (D) respectively. In all cases, conditions of “no activating reagent” are showed by white bars, conditions with Mg^{2+} /EGTA

(for $\alpha\text{L}\beta 2$ adhesion) or Mn^{2+} (for $\alpha\text{M}\beta 2$ and $\alpha\text{X}\beta 2$ adhesion) showed by grey bars, conditions with KIM185 showed in black, and conditions with Mg^{2+} /EGTA together with KIM185 showed in hatched bars. The significant level was set at 0.05: ns (not significant); * ($p\text{-value} < 0.05$).

- Fig. 5. The resting (A) and active (B) structure of the βI domain of the $\alpha\text{X}\beta 2$ integrin. The resting state was that of PDB ID: 3K6S (from [43]) and the active state was that of PDB ID: 4NEH (from [44]). The location of G150 was shown to be at the top of $\alpha 1'$ helix in the resting state but in the extended $\alpha 1$ helix in the active state. Coordinating residues of SyMBS were labeled in yellow, that of MIDAS were labeled in magenta and that of ADMIDAS were labeled in white. The NMR structures of the $\beta 2$ peptides spanning the $\alpha 1$ and $\alpha 1'$ helices "SMLDDLRLNVKKL(G/D)GDLLRALNEI" are shown with the wild-type glycine in (C) and the mutant aspartic acid in (D).

Fig. 1

Fig. 2

		P		R		P
β2	42	GCTWCQKLNFT...	56	DPDSIRCDTRPQLLMR...	102	KVTLYLRPGQAA
β1	44	NCGWCTNSTFL...	58	MPTSARCDLEALKKK...	117	QLVLRRLRSGEFQ
β3	48	MCAWCSDEALP...	61	SP--RCDLKENLLKD...	113	RIALRLRPFDDSK
β4	47	DCAYCTDEMER...	58	DR--RCNTQAEELAA...	105	GLRVLRPFGEER
β5	45	KCAWCSKEDFG...	58	RSITSRCDLRANLVKN...	113	EIAVNLRPGDKT
β6	40	QCAWCAQENFT...	54	GVGE-RCDTPANLLAK...	105	SLILKLRPGGAQ
β7	60	SCAWCKQLNFT...	74	EAEARRCARREELLAR...	127	RVRVTLRPFGEFQ
β8	64	ECGWCVQEDFT...	78	SRSE-RCDIVSNLISK...	122	EVSTQLRPGAEA
		Y	N	D	E	NT
β2	126	PIDLYYIMDLSYS...	148	KLGGDL...	172	VDKTVL...236 GLDAMMQ
β1	141	PIDLYYIMDLSYS...	163	SLGTDL...	187	VEKTVM...250 GFDAIMQ
β3	137	PVDIYYIMDLSYS...	159	NLGTKL...	183	VDKPVV...248 GFDAIMQ
β4	129	PVDLYILMDFSNS...	151	KMGQNL...	175	VDKVS...235 GFDAILQ
β5	137	PVDLYYIMDLSS...	159	SLGTKL...	183	VDKDIS...249 GFDAILQ
β6	132	PVDLYYIMDLSS...	154	ELGSRL...	178	VEKPVV...242 GFDAIMQ
β7	151	PVDLYYIMDLSS...	173	QLGHAL...	197	VDKTVL...261 GFDAILQ
β8	146	PVDLYYLVDSAS...	168	SVGNDL...	192	VDKTVS...256 GFDAILQ
		W	K	V L	R	
β2	255	VTRLLV...280	TPNDGRCHLEDN-LYKRSNEFDYPSV...	451	DQSRDRS	
β1	269	VTRLLV...294	LPNDGQCHLENN-MYTMShYYDYPSI...	467	SEGIPEP	
β3	268	ASHLLV...293	QPNDDGQCHVGSNDHYSASTMDYPSL...	465	AQAEFNS	
β4	255	STHLLV...282	SRNDRCHLDTTGTQYRTQDYPSV...	459	LQKEVRS	
β5	269	ALHLLV...294	QPHDGGCHLNEANEYTSNQMDYPSL...	467	VGLEPNS	
β6	262	SLHLLV...287	IPNDGLCHLDSKNEYSMTVLEYPTI...	458	KEVEVNS	
β7	280	VSRLLV...305	MPSDGHCHLDSNGLYSRSTEFDYPSV...	479	SDTQPPA	
β8	276	AKRLLL...301	VPNDGNCHLKNN-VYVKSTTMEHPSL...	473	DNRGPKG	
		S	R	L	A	
β2	553	GRGLCFCKGKRC...	610	PLCQEC...	646	ACEGL...714 LIGILLV
β1	569	GNGVCKCRVCEC...	627	QTCQTC...	663	ECSYF...741 LIGLALL
β3	564	GHGQCSGDCCLC...	622	DTCPPTC...	660	YCRDE...732 LIGLAALL
β4	553	DRGRCSMGQCVC...	611	DTICEIN...	650	ECNFK...724 LLALLLN
β5	565	GHGECHGCECKC...	623	EMCPPTC...	660	LCRDE...733 LVGLALLA
β6	554	GNGDCDCGECVC...	612	PTCPPTC...	648	KCKLA...721 LIGVVLLC
β7	576	GFGRCCGVCVHC...	633	ALCQPC...	669	ACAHT...737 LVGLGLV
β8	563	GHGECEAGRCQC...	622	RFCPTC...	660	SCA--...729 KDGLLVV

Fig. 3

Fig. 4

Fig. 5

Table

Mutation	Domain	Cons ^a	Expression	Adhesion	Ref.
M1K	PSI	8	ND ^d		[5]
C36S	PSI	8	Diminished expression of $\alpha\text{L}\beta 2$; $\alpha\text{M}\beta 2$ and $\alpha\text{X}\beta 2$	Constitutive $\alpha\text{L}\beta 2$ adhesion to ICAM-1	[4] [6]
T44P ^b	PSI	1	No		[4]
C62R ^b	PSI	8	No		[4]
L105P ^b	Hybrid	4	No		[4] [7]
D128N	βI	8	ND ^d		[8]
D128Y ^b	βI	8	No		[4] [9]
Y131S	βI	8	No		[10]
D134N ^b	βI	8	No		[4] [11]
S138P	βI	8	Normal	No adhesion function	[12]
L149P	βI	6	No		[13] [14]
G150D ^b	βI	8	Normal	No adhesion function	[15]
G169R	βI	8	No		[13] [16]
K174E ^b	βI	8	No		[4]
P178L	βI	8	No		[17] [18] [19]
D231H	βI	8	Normal $\alpha\text{L}\beta 2$ expression, diminished $\alpha\text{M}\beta 2$ and $\alpha\text{X}\beta 2$ expression	No adhesion function	[20]
D238N ^b	βI	8	No		[4]
A239T ^b	βI	8	No		[9]
W252R	βI	8	No		[21]
R257W ^b	βI	4	No		[4]
A270V	βI	6	No $\alpha\text{L}\beta 2$ expression, diminished $\alpha\text{M}\beta 2$ and $\alpha\text{X}\beta 2$ expression	No adhesion function	[22]
G273R	βI	6	No		[12]
N282K ^b	βI	6	No		[4]
G284S	βI	7	No		[10] [14]
D300V ^b	βI	6	No		[4] [23]
P302L ^b	βI	8	No		[4]
A341P	βI	3	Detectable expression for $\alpha\text{L}\beta 2$, no expression for $\alpha\text{M}\beta 2$ and $\alpha\text{X}\beta 2$	Detectable adhesion on ICAM-1 with $\alpha\text{L}\beta 2$	[22]
N351S	βI	8	Normal $\alpha\text{L}\beta 2$ expression and diminished $\alpha\text{M}\beta 2$ and $\alpha\text{X}\beta 2$ expression ^e	Active $\alpha\text{L}\beta 2$ adhesion to ICAM-1 and ICAM-3. Diminished adhesion properties of $\alpha\text{M}\beta 2$ and $\alpha\text{X}\beta 2$ ^e	[6] [24] [25] [26]
S453N ^{b,c}	IEFG-1	1	Normal	Normal	[4]
C557S ^b	IEFG-3	8	No		[4]
C590R	IEFG-4	8	Diminished $\alpha\text{L}\beta 2$ and $\alpha\text{X}\beta 2$ expression, no $\alpha\text{M}\beta 2$ expression	Constitutive $\alpha\text{L}\beta 2$ adhesion to ICAM-1, minimal adhesion for $\alpha\text{M}\beta 2$ and $\alpha\text{X}\beta 2$	[22]
R593C	IEFG-4	7	Diminished $\alpha\text{L}\beta 2$ and $\alpha\text{X}\beta 2$ expression, no $\alpha\text{M}\beta 2$ expression	Constitutive $\alpha\text{L}\beta 2$ adhesion to ICAM-1, minimal adhesion for $\alpha\text{M}\beta 2$ and $\alpha\text{X}\beta 2$	[2] [22] [27]
C612R ^b	IEFG-4	8	No		[4] [28] [29]
P648L ^{b,c}	β tail	1	Normal	Normal	[4]
G716A ^b	TM	7	Normal	Constitutive $\alpha\text{L}\beta 2$ adhesion to ICAM-1, elevated adhesion for $\alpha\text{M}\beta 2$ and $\alpha\text{X}\beta 2$ to denatured BSA	[4] [9]

a: Conservation among the 8 human integrin β subunits

b: This study

c: Most likely rare polymorphisms

d: ND, not done

e: S.K.A. Law, unpublished result

Supplementary Figure A1

Supplementary Figure A1. Flow cytometry analysis of the surface expression of (A) CD11b/CD18 (Mac-1); and (B) CD11c/CD18 (p150,95) transfectants with the various mutations. The mAb used was MHM23 which is specific for the CD18 integrin heterodimers [30]. The background histograms were obtained with MHM24 (CD11a-specific).